I thought this video over on the LLS Community page was interesting.
https://communityvie...clinical-trials
Video interview - Evolving CML Research: Assessing the Need for Ongoing Treatment in Clinical Trials
Started by
Red Cross Kirk
, Feb 21 2017 12:11 AM
cessation ABL001 ASH 2016 Dr. Jessica Altman clinical trials
No replies to this topic
#1
Red Cross Kirk
-
- Members
-
- 173 posts
Advanced Member
- LocationOregon
Posted 21 February 2017 - 12:11 AM
Kirk
9/25/2012 p210 transcript 118.7% IS @ Dx, begin Gleevec 400mg/day
12/2012 3.59% & bone marrow biopsy - no residual myeloproliferative features but detected 1/20 metaphases containing the Philadelphia chromosome
2013 0.914%, 0.434%, 0.412%
10/2013 0.360% & bone marrow biopsy - normal male karyotype with no evidence of a clonal cytogenetic abnormaltiy
2014 0.174%, 0.088%, 0.064%
2015 0.049%, decrease to Gleevec 200mg/day, 0.035%, 0.061%, 0.028%
2016 0.041%, 0.039%, 0.025%
2017 0.029%, 0.039%, switched to generic imatinib 200mg/day, 0.070%, 0.088%
2018 0.233%
Also tagged with one or more of these keywords: cessation, ABL001, ASH 2016, Dr. Jessica Altman, clinical trials
The Leukemia & Lymphoma Society Community →
LLS Blood Cancer Discussion Boards →
Chronic Myeloid Leukemia →
New video on ABL001 in patients with CMLStarted by survenant , 15 May 2016  cml, CML, ABL001
|
|
|
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
